RETROSPECTIVE STUDY OF ERLOTINIB IN PREVIOUSLY TREATED NSCLC PATIENTS WITH WILD-TYPE EGFR

被引：0

作者：

Nakahara, Yoshiro ^{[1
]}

Hosomi, Yukio ^{[1
]}

Yomota, Makiko ^{[1
]}

Okuma, Yusuke ^{[1
]}

Takagi, Yusuke ^{[1
]}

Iguchi, Mari ^{[1
]}

Okamura, Tatsuru ^{[1
]}

机构：

[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期

关键词：

wild-type EGFR; Erlotinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2-034

引用

页码：S490 / S490

页数：1

共 50 条

[1] Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis
Inno, Alessandro
Di Noia, Vincenzo
Martini, Maurizio
D'Argento, Ettore
Di Salvatore, Mariantonietta
Arena, Vincenzo
Schinzari, Giovanni
Orlandi, Armando
Larocca, Luigi Maria
Cassano, Alessandra
Barone, Carlo
PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (02) : 513 - 520
[2] Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
Li, Yang-Ling
Hu, Xiu
Li, Qing-Yu
Wang, Fei
Zhang, Bo
Ding, Ke
Tan, Bi-Qin
Lin, Neng-Ming
Zhang, Chong
MOLECULAR MEDICINE REPORTS, 2018, 18 (04) : 3882 - 3890
[3] Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors
Toffalorio, Francesca
de Marinis, Filippo
Conforti, Fabio
Spitaleri, Gianluca
Catania, Chiara
Noberasco, Cristina
Lazzari, Chiara
Vecchio, Fabio
Stufano, Viviana
Barberis, Massimo
De Pas, Tommaso
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 392 - 396
[4] Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L
Kimura, T.
Kawaguchi, T.
Kudoh, S.
Chiba, Y.
Yoshioka, H.
Watanabe, K.
Kijima, T.
Kogure, Y.
Oguri, T.
Yoshimura, N.
Niwa, T.
Kasai, T.
Hayashi, H.
Ono, A.
Tanaka, H.
Yano, S.
Nakamura, S.
Yamamoto, N.
Nakanishi, Y.
Nakagawa, K.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2129 - S2129
[5] EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
Jassem, Jacek
Dziadziuszko, Rafal
LANCET ONCOLOGY, 2013, 14 (10) : 916 - 917
[6] Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study
Tamura, T.
Baba, T.
Umeno, T.
Nishii, K.
Kuyama, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S641 - S641
[7] Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients with Wild-Type EGFR: TORG 1320
Hosokawa, S.
Otani, S.
Sasaki, J.
Fukui, T.
Nakahara, Y.
Bessho, A.
Fukamatsu, N.
Nakamura, Y.
Kasai, T.
Sugiyama, T.
Tokitho, T.
Seki, N.
Hamada, A.
Masuda, N.
Okamoto, H.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S881 - S882
[8] Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study
De Castro, Javier
Bernabe, Reyes
Angeles Sala, M.
Puente, Javier
Vazquez, Sergio
Majem, Margarita
Rosario Garcia-Campelo, M.
Paredes, Alfredo
Lopez, Rafael
Girones, Regina
Diz, Pilar
Gomez-Codina, Jose
Triguboff, Alberto
Terrancle, Angeles
Gordo, Rocio
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S235 - S235
[9] ERLOTINIB IN METASTATIC, EGFR WILD-TYPE, NON-SMALL CELL LUNG CANCER (NSCLC) AS SECOND OR FURTHER LINE OF THERAPY
Hernandez, Alba
Calera, Lourdes
Alvarez, Maria
Hernando, Jorge
Torres, Irene
Pajares, Isabel
Madani, Julia
Cebollero, Ana
Anton-Torres, Antonio
Artal, Angel
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1017 - S1017
[10] A Phase II Study of Carboplatin/Pemetrexed/Bevacizumab Followed by Bevacizumab/Erlotinib Maintenance for NonSq-NSCLC with Wild-Type EGFR
Yokouchi, Hiroshi
Takashina, Taichi
Asahina, Hajime
Yamada, Noriyuki
Harada, Masao
Nakano, Kosuke
Kanazawa, Kenya
Takamura, Kei
Ogi, Takahiro
Harada, Toshiyuki
Honjo, Osamu
Morikawa, Naoto
Kinoshita, Ichiro
Honda, Ryoichi
Amano, Toraji
Dosaka-Akita, Hirotoshi
Isobe, Hiroshi
Nishimura, Masaharu
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S546 - S546

← 1 2 3 4 5 →